Add BrightSurf on Google Email

Massachusetts General Hospital


Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder

A clinical trial shows that romiplostim significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura (ITP), a hematologic disorder that can cause uncontrolled bleeding. The novel drug duplicates the action of a natural hormone discovered by MGH investigator, offering low toxicity and high response rates.

SourceMassachusetts General Hospital·JournalThe Lancet·DateJan 31, 2008

Second phase of HapMap project is completed

The International HapMap Project has completed its second phase, tripled the amount of genetic variation assessed and describes up to 95% of common single-letter variations in the human genetic code. This increased density of identified SNPs allows researchers to better understand disease-associated genes and detect rare disease variants.

Skin as a living coloring book

Scientists at Massachusetts General Hospital found that the Foxn1 gene determines where pigment is deposited in the epidermis and hair. The study reveals that melanocytes deliver melanin to specific cells indicated by the Foxn1 gene, which acts as a map for pigment distribution.

Molecular signature may identify cisplatin-sensitive breast tumors

Researchers at MGH Cancer Center have discovered a molecular pathway underlying sensitivity to cisplatin in triple-negative breast cancers. The study found that p63 and p73 expression levels can predict cisplatin therapy effectiveness, leading to the design of a clinical trial for patients with advanced triple-negative breast cancer.

SourceMassachusetts General Hospital·JournalJournal of Clinical Investigation·DateApr 19, 2007